新辅助化疗对非小细胞肺癌患者淋巴细胞免疫功能的影响及治疗

Effects of neoadjuwant chemotherapy on cell immunofunction in patients of NSCLC and therapy

目的观察新辅助化疗或新辅助化疗联合康莱特治疗对非小细胞肺癌(NSCLC)患者淋巴细胞免疫功能的影响。方法54例NSCLC初治患者按治疗方式分成A组(单纯新辅助化疗)28例,B组(新辅助化疗+康莱特治疗)26例,在治疗前后检测患者淋巴细胞免疫的变化。结果 A组(单纯新辅助化疗):治疗后CD_3、CD_4、CD_8、NK细胞明显下降,前、后对比均P<0.05;CD_4/CD_8下降,但P>0.05。B组(新辅助化疗+康莱特治疗):治疗后CD_3、CD_4、CD_8、NK细胞下降,CD_4/CD_8上升,但前、后对比均P>0.05。结论新辅助化疗使NSCLC患者淋巴细胞免疫功能明显下降,联合康莱特治疗能使细胞免疫功能明显改善。

OBJECTIVE To observe the effects of neoadjuwant chemotherapy and neoadjuwant chemotherapy plus KLT on cell immunofunction in patients of NSCLC and therapy.METHOD 26 patients of NSCLC were rolled in A team,treated with neoadjuwant chemotherapy only;and 28 patients of NSCLC were rolled in A team,treated with neoadjuwant chemotherapy combined with KLT.The peripheral blood samples were evaluated with the flow cytometry for T-lymphocyte subsets and NK cell before and after neoadjuwant chemotherapy.RESULTS The level of CD_3、CD_4、CD_8、NK cell were significantly decreased compared with that before therapy in A team respectively(P <0.05),and the level of CD4/CD8 was decreased(P > 0.05);The level of CD_3、CD_4、CD_8、 NK cell were decreased compared with that before therapy in B team respectively(P > 0.05),and the level of CD_4/CD_8 was increased(P > 0.05).CONCLUSION The cell immunity was impaired considerably by neoadjuwant chemotherapy.Neoadjuwant chemotherapy combined with KLT can enhance the cell immunity considerably.